Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline (Alzheimer's Research & Therapy, (2020), 12, 1, (169), 10.1186/s13195-020-00738-8): Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline (Alzheimer's Research & Therapy, (2020), 12, 1, (169), 10.1186/s13195-020-00738-8)

Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen, Klaus Gerwert*

*Corresponding author for this work

Research output: Contribution to journalErratumAcademicpeer-review

Abstract

Following publication of the original article [1], the authors noticed that the published figures have errors which was occurred during processing of the figures in production team. 1) fonts are shifted (Figure 1) 2) colors are not displayed (Figure 2, open circles should be colored) 3) labelling is incorrect (Figure 4, "Afl" should be "Aß", Supplementary Figures "D Absorbance" should be "? absorbance" (Δ = delta)) The correct Figures 1, 2 and 4 are shown below. The original article [1] has been updated. (Figure presented.).
Original languageEnglish
Article number25
JournalAlzheimer's Research and Therapy
Volume13
Issue number1
DOIs
Publication statusPublished - 1 Dec 2021

Cite this